Robert Weiss, M.D.

Robert H. Weiss, M.D.


Internal Medicine



Internal Medicine


Robert H. Weiss is not currently accepting new patients. For assistance finding a UC Davis doctor, please call 800-2-UCDAVIS (800-282-3284).

Clinical Interests

Robert H. Weiss' clinical interests include the diagnosis and treatment of all renal diseases and electrolyte problems. His research interests concern the cyclins and cyclin inhibitors, cancer growth control (kidney and breast cancer), metabolomics and proteomics, and polycystic kidney disease.



Center/Program Affiliation

UC Davis Comprehensive Cancer Center


M.D., UC Irvine College of Medicine, Irvine CA 1984

M.S., Physical Chemistry, UCLA, Los Angeles CA 1978

M.S., Medical Physics, UCLA, Los Angeles CA 1980

B.A., UC Santa Cruz, Santa Cruz CA 1976

Internship: Internal Medicine, California-Pacific Medical Center, San Francisco CA 1984-1985


Internal Medicine, California-Pacific Medical Center, San Francisco CA 1985-1987


Nephrology, UC San Francisco, San Francisco CA 1991

Board Certifications

American Board of Internal Medicine, 1987

American Board of Internal Medicine, Nephrology, 1996

Professional Memberships

American Association for the Advancement of Science

American College of Physicians

American Society of Nephrology

Select Recent Publications

Kim J, Ulu A, Wan D, Yang J, Hammock BD, Weiss RH. Addition of DHA synergistically enhances the efficacy of regorafenib for kidney cancer therapy. Mol Cancer Ther. 2016 Feb 26. [Epub ahead of print]

Hu SL, Chang A, Perazella MA, Okusa MD, Jaimes EA, Weiss RH; American Society of Nephrology Onco-Nephrology Forum. The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma. J Am Soc Nephrol. 2016 Mar 9. [Epub ahead of print]

Wettersten HI, Hakimi AA, Morin D, Bianchi C, Johnstone ME, Donohoe DR, Trott JF, Aboud OA, Stirdivant S, Neri B, Wolfert R, Stewart B, Perego R, Hsieh JJ, Weiss RH. Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis. Cancer Res. 2015 Jun 15;75(12):2541-52.

Hwang VJ, Kim J, Rand A, Yang C, Sturdivant S, Hammock B, Bell PD, Guay-Woodford LM, Weiss RH. The cpk model of recessive PKD shows glutamine dependence associated with the production of the oncometabolite 2-hydroxyglutarate. Am J Physiol Renal Physiol. 2015 Sep 15;309(6):F492-8.

Abu Aboud O, Donohoe D, Bultman S, Fitch M, Riiff T, Hellerstein M, Weiss RH. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth. Am J Physiol Cell Physiol. 2015 Jun 1;308(11):C890-8.

Wettersten HI, Landesman Y, Friedlander S, Shacham S, Kauffman M, Weiss RH. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth. PLoS One. 2014 Dec 2;9(12):e113867.

Tan M, Wettersten HI, Chu K, Huso DL, Watnick T, Friedlander S, Landesman Y, Weiss RH. Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels. Am J Physiol Renal Physiol. 2014 Dec 1;307(11):F1179-86.

Ganti S, Taylor SL, Kim K, Hoppel CL, Guo L, Yang J, Evans C, Weiss RH. Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer. 2012 Jun 15;130(12):2791-800.

Ganti, S., Taylor,S.L., Aboud,O.A., Yang,J., Evans,C., Osier,M.V., Alexander,D.C., Kim,K., Weiss,R.H. Simultaneous multiple matrix metabolomics analysis of a mouse kidney cancer xenograft yields potential tumor biomarkers. Cancer Research. 2012; Jul 15;72(14):3471-9.

Weiss RH, Kim K. Metabolomics in the study of kidney diseases. Nat Rev Nephrol. 2011 Oct 25;8(1):22-33.